{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T21:56:56Z","timestamp":1795039016521,"version":"4.10.2"},"reference-count":36,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,10,5]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>A phase 1 trial of the anti-CD22 immunotoxin moxetumomab pasudotox was conducted in children with ALL. A 32% objective response rate was observed, including 11 composite complete responses (23%), 5 of which were minimal residual disease negative.<\/jats:p>","DOI":"10.1182\/blood-2017-02-749101","type":"journal-article","created":{"date-parts":[[2017,8,9]],"date-time":"2017-08-09T21:20:22Z","timestamp":1502313622000},"page":"1620-1627","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":57,"title":["Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"130","author":[{"given":"Alan S.","family":"Wayne","sequence":"first","affiliation":[{"name":"Children\u2019s Center for Cancer and Blood Diseases, Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children\u2019s Hospital Los Angeles, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA;"},{"name":"Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD;"},{"name":"Laboratory of Molecular Biology, CCR, NCI, NIH, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Bhojwani","sequence":"additional","affiliation":[{"name":"Children\u2019s Center for Cancer and Blood Diseases, Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children\u2019s Hospital Los Angeles, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA;"},{"name":"St Jude Children\u2019s Research Hospital, Memphis, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis B.","family":"Silverman","sequence":"additional","affiliation":[{"name":"Pediatric Hematologic Malignancies Center, Dana-Farber Cancer Institute\/Boston Children\u2019s Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Whitlock","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryalice","family":"Stetler-Stevenson","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, CCR, NCI, NIH, Bethesda, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Sun","sequence":"additional","affiliation":[{"name":"Children\u2019s Center for Cancer and Blood Diseases, Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children\u2019s Hospital Los Angeles, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meina","family":"Liang","sequence":"additional","affiliation":[{"name":"MedImmune, Gaithersburg, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[{"name":"MedImmune, Gaithersburg, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Kreitman","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, CCR, NCI, NIH, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Lanasa","sequence":"additional","affiliation":[{"name":"MedImmune, Gaithersburg, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, CCR, NCI, NIH, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"14","key":"2019111900171666100_B1","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children\u2019s Oncology Group","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111900171666100_B2","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1200\/JCO.2009.22.2950","article-title":"Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study","volume":"28","author":"Ko","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111900171666100_B3","unstructured":"Gloeckler Ries\n              LA\n            \n          . Childhood cancer mortality. In: ReisLAG, SmithMA, GurneyJG, , eds. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Institutes of Health; 1999. NIH publication no. 99-4649."},{"issue":"15","key":"2019111900171666100_B4","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMsa060185","article-title":"Chronic health conditions in adult survivors of childhood cancer","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N Engl J Med"},{"issue":"31","key":"2019111900171666100_B5","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1200\/JCO.2012.41.6768","article-title":"Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111900171666100_B6","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pbc.25410","article-title":"Characterization of CD22 expression in acute lymphoblastic leukemia","volume":"62","author":"Shah","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"16","key":"2019111900171666100_B7","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1182\/blood-2014-01-492256","article-title":"Immunotoxins for leukemia","volume":"123","author":"Wayne","year":"2014","journal-title":"Blood"},{"issue":"15","key":"2019111900171666100_B8","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.1158\/0008-5472.CAN-08-0461","article-title":"Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity","volume":"68","author":"Du","year":"2008","journal-title":"Cancer Res"},{"issue":"5","key":"2019111900171666100_B9","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood.V90.5.2020","article-title":"Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors","volume":"90","author":"Mansfield","year":"1997","journal-title":"Blood"},{"issue":"6","key":"2019111900171666100_B10","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-09-2980","article-title":"Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial","volume":"16","author":"Wayne","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019111900171666100_B11","first-page":"995","article-title":"Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display","volume":"8","author":"Salvatore","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019111900171666100_B12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08251.x","article-title":"Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia","volume":"150","author":"Mussai","year":"2010","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111900171666100_B13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cyto.b.20567","article-title":"Variables affecting the quantitation of CD22 in neoplastic B cells","volume":"80","author":"Jasper","year":"2011","journal-title":"Cytometry B Clin Cytom"},{"issue":"8","key":"2019111900171666100_B14","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/sj.leu.2403001","article-title":"Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children\u2019s Oncology Group study","volume":"17","author":"Borowitz","year":"2003","journal-title":"Leukemia"},{"issue":"6","key":"2019111900171666100_B15","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1002\/btpr.1983","article-title":"Development and scale-up of a commercial fed batch refolding process for an anti-CD22 two chain immunotoxin","volume":"30","author":"Linke","year":"2014","journal-title":"Biotechnol Prog"},{"key":"2019111900171666100_B16","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events, version 3.0. Available at: http:\/\/ctep.cancer.gov\/reporting\/ctc.html. Accessed 4 November 2016."},{"issue":"24","key":"2019111900171666100_B17","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [published correction appears in J Clin Oncol. 2004;22(3):576]","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111900171666100_B18","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1200\/JCO.2011.38.1756","article-title":"Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia","volume":"30","author":"Kreitman","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111900171666100_B19","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.bbmt.2010.08.001","article-title":"NCI First International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the Committee on Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"16","author":"Porter","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2019111900171666100_B20","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.bbmt.2013.08.016","article-title":"Proceedings from the National Cancer Institute\u2019s Second International Workshop on the biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation: introduction","volume":"19","author":"Wayne","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2019111900171666100_B21","first-page":"1476","article-title":"Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias","volume":"6","author":"Kreitman","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"26","key":"2019111900171666100_B22","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"issue":"16","key":"2019111900171666100_B23","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"18","key":"2019111900171666100_B24","doi-asserted-by":"crossref","first-page":"6898","DOI":"10.1073\/pnas.1204523109","article-title":"Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy","volume":"109","author":"Wei","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"2019111900171666100_B25","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.leukres.2013.08.005","article-title":"Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8","volume":"37","author":"Hu","year":"2013","journal-title":"Leuk Res"},{"issue":"19","key":"2019111900171666100_B26","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1158\/1078-0432.CCR-15-2500","article-title":"Wide variability in the time required for immunotoxins to kill B lineage acute lymphoblastic leukemia cells: implications for trial design","volume":"22","author":"M\u00fcller","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"18","key":"2019111900171666100_B27","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1200\/JCO.2008.20.2630","article-title":"Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia","volume":"27","author":"Kreitman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111900171666100_B28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJM200107263450402","article-title":"Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia","volume":"345","author":"Kreitman","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111900171666100_B29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev"},{"issue":"12","key":"2019111900171666100_B30","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","article-title":"Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"24","author":"Jeha","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111900171666100_B31","first-page":"245","article-title":"Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins","volume":"2","author":"Reiter","year":"1996","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111900171666100_B32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/imr.12390","article-title":"Immunogenicity of therapeutic recombinant immunotoxins","volume":"270","author":"Mazor","year":"2016","journal-title":"Immunol Rev"},{"issue":"22","key":"2019111900171666100_B33","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","article-title":"Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children\u2019s Oncology Group pilot study","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111900171666100_B34","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111900171666100_B35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/pbc.24721","article-title":"Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia","volume":"61","author":"Rytting","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"2019111900171666100_B36","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/14\/1620\/1402658\/blood749101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/14\/1620\/1402658\/blood749101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:17:30Z","timestamp":1574122650000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/14\/1620\/107642\/Phase-1-study-of-the-antiCD22-immunotoxin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,5]]},"references-count":36,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2017,10,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-02-749101","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,5]]}}}